News
Transplant antiviral strong in phase 2; Chimerix plans phase 3 start this year
WRAL Tech Wire
February 6, 2012
Chimerix Announces Presentation of Final Data from CMX001 Phase 2 Trial in Prophylaxis of Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients
International Drug Discovery
January 27, 2012
Chimerix Announces Late-Breaker Presentation At 51st Interscience Conference On Antimicrobial Agents And Chemotherapy (ICAAC) Annual Meeting
The Street
September 16, 2011
Chimerix Awarded BARDA Contract for Advanced Development of CMX001 as Medical Countermeasure Against Smallpox
Download the PDF
February 16, 2011
Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
Download the PDF
February 14, 2011
Chimerix
Durham, NC
Chimerix is developing a range of antiviral medicines for the treatment of life-threatening diseases. Its product candidates derive from Phospholipid Intramembrane Microfluidization Conjugate Technology, which can enhance the activity, bioavailability and safety of useful drugs. Chimerix’s lead compound, CMX001, is a broad-spectrum oral antiviral agent initially being developed for the treatment of CMV and AdV5 in transplant patients.